CLEVELAND, Jan. 5 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. , a technology company focused on global eClinical solutions for the clinical trials industry, today reported that during the month of December it was awarded 18 contracts from seven clinical trial sponsors. Four of the sponsors have headquarters in the United States and three are based in Europe. These new contracts have an initial value of approximately $4.7 million and represent a new financial record of monthly business for the Company.
Also during the month of December, DATATRAK added the 57th country where its software suites have been utilized with new users located in the Philippines.
"We are very pleased to add this significant new amount of new business from such a diversification of current and new customers, especially during a month that can sometimes be slow in this industry," stated Dr. Jeffrey A. Green, President and Chief Executive Officer of DATATRAK International, Inc. "This dollar magnitude of new business is a monthly record for the Company. One of the new clients is leveraging the advantages of our unified platform by using DATATRAK eClinical(TM) in the same clinical trial for electronic data capture (EDC) and digital electrocardiographic (ECG) collection. The ability to have both information sets in a single database, without the need for integration, is unique in this industry. Our pipeline of additional new business opportunities and the demand in the industry for DATATRAK eClinical(TM) is strong and continues to build as we enter 2007."
DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Technology Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 57 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 separate drugs that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, Bonn, Germany, and Bryan, Texas. Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA." Visit the DATATRAK International, Inc. web site at www.datatrak.net.
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations and beliefs concerning future events impacting the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the ability of the Company to absorb corporate overhead and other fixed costs in order to successfully market its software; the development and fluctuations in the market for clinical trial technology; the degree of the Company's success in obtaining new contracts; the timing of payments from customers and the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; governmental regulation; the early stage of the Company's business and operations; and general economic conditions. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry.
DATATRAK International, Inc.CONTACT: Jeffrey A. Green, Pharm.D., FCP, President and Chief ExecutiveOfficer, +1-440-443-0082 x112, or Terry C. Black, Chief Financial Officer,+1-440-443-0082 x110, both of DATATRAK International, Inc.; or NealFeagans, Investor Relations, of Feagans Consulting, Inc., +1-303-449-1184
Web site: http://www.datatrak.net/
